Your browser doesn't support javascript.
loading
Cell of origin of transformed follicular lymphoma.
Kridel, Robert; Mottok, Anja; Farinha, Pedro; Ben-Neriah, Susana; Ennishi, Daisuke; Zheng, Yvonne; Chavez, Elizabeth A; Shulha, Hennady P; Tan, King; Chan, Fong Chun; Boyle, Merrill; Meissner, Barbara; Telenius, Adele; Sehn, Laurie H; Marra, Marco A; Shah, Sohrab P; Steidl, Christian; Connors, Joseph M; Scott, David W; Gascoyne, Randy D.
Afiliación
  • Kridel R; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, and.
  • Mottok A; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, and.
  • Farinha P; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, and.
  • Ben-Neriah S; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Ennishi D; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Zheng Y; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Chavez EA; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Shulha HP; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Tan K; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Chan FC; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Boyle M; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Meissner B; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Telenius A; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada;
  • Sehn LH; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
  • Marra MA; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; and.
  • Shah SP; Department of Pathology and Laboratory Medicine, and Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada.
  • Steidl C; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, and.
  • Connors JM; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
  • Scott DW; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
  • Gascoyne RD; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, and.
Blood ; 126(18): 2118-27, 2015 Oct 29.
Article en En | MEDLINE | ID: mdl-26307535
Follicular lymphoma (FL) is an indolent disease but transforms in 2% to 3% of patients per year into aggressive, large cell lymphoma, a critical event in the course of the disease associated with increased lymphoma-related mortality. Early transformation cannot be accurately predicted at the time of FL diagnosis and the biology of transformed FL (TFL) is poorly understood. Here, we assembled a cohort of 126 diagnostic FL specimens including 40 patients experiencing transformation (<5 years) and 86 patients not experiencing transformation for at least 5 years. In addition, we assembled an overlapping cohort of 155 TFL patients, including 114 cases for which paired samples were available, and assessed temporal changes of routinely available biomarkers, outcome after transformation, as well as molecular subtypes of TFL. We report that the expression of IRF4 is an independent predictor of early transformation (Hazard ratio, 13.3; P < .001). We also show that composite histology at the time of transformation predicts favorable prognosis. Moreover, applying the Lymph2Cx digital gene expression assay for diffuse large B-cell lymphoma (DLBCL) cell-of-origin determination to 110 patients with DLBCL-like TFL, we demonstrate that TFL is of the germinal-center B-cell-like subtype in the majority of cases (80%) but that a significant proportion of cases is of the activated B-cell-like (ABC) subtype (16%). These latter cases are commonly negative for BCL2 translocation and arise preferentially from BCL2 translocation-negative and/or IRF4-expressing FLs. Our study demonstrates the existence of molecular heterogeneity in TFL as well as its relationship to the antecedent FL.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos B / Transformación Celular Neoplásica / Linfoma Folicular / Proteínas Proto-Oncogénicas c-bcl-2 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos B / Transformación Celular Neoplásica / Linfoma Folicular / Proteínas Proto-Oncogénicas c-bcl-2 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos